What makes a drug a blockbuster — or a cautionary tale?

Off Alzheimer's disease, Alzheimer’s, Biotech, biotechnology, Business, drug development, drug prices, drug pricing, finance, Health, Human Health, Life Sciences, Medicine, opioids, Pharma, pharmaceutical industry, Pharmaceuticals, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. Today, we talk about how biomanufacturing is getting a huge boost in North Carolina, study a new potential root for autoimmune disease in women, and more.

Read the rest…

Read Original Article: What makes a drug a blockbuster — or a cautionary tale? »

About The Author